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Abstract  
Background and Aims: Advancing liver disease results in deleterious changes in a number of 
critical organs. The ability to measure structure, blood flow and tissue perfusion within 
multiple organs in a single scan has implications for determining the balance of benefit versus 
harm for therapies. Our aim was to establish the feasibility of Magnetic Resonance Imaging 
to assess changes in compensated cirrhosis (CC), and relate this to disease severity and future 
liver related outcomes (LROs).  
Methods: 60 CC patients, 40 healthy volunteers and 7 decompensated cirrhotics were 
recruited. In a single scan session, MRI measures comprised phase-contrast MRI vessel blood 
flow, arterial spin labelling tissue perfusion, T1 longitudinal relaxation time and volume 
assessment of liver, spleen and kidneys, heart rate and cardiac index. We explore MRI 
parameters with disease severity and differences in baseline MRI parameters in those 11 
(18%) of CC patients who had future LROs.  
Results: In the liver compositional changes were reflected by increased T1 in progressive 
disease (p<0.001) and an increase in liver volume in CC (p=0.006), with associated progressive 
reduction in liver (p < 0.001) and splenic (p<0.001) perfusion. A significant reduction in renal 
cortex T1 and increase in cardiac index and superior mesenteric arterial (SMA) blood flow was 
seen with increasing disease severity. Baseline liver T1 (p=0.01) and perfusion (p< 0.01), and 
renal cortex T1 (p<0.01) were significantly different in CC patients who subsequently 
developed negative LROs.  
Conclusions: MRI allows the contemporaneous assessment of organs in liver cirrhosis in a 
single scan without the requirement of contrast agent. MRI parameters of liver T1, renal T1,  
hepatic and splenic perfusion, and SMA blood flow were related to risk of LROs.  
 Lay Summary  
This study assesses the changes to structure, blood flow and perfusion that occur in the key 
organs (liver, spleen and kidney) associated with severe liver disease (compensated cirrhosis). 
Those MRI measures which change with disease severity and are related to negative liver 
related clinical outcomes are described.  
 
Graphical Abstract 
 
 
Highlights  
 Assessment of MRI parameters in a single scan session. 
 Higher liver T1 and reduced liver perfusion with increasing disease severity and 
clinical outcomes. 
 Reduced renal cortex T1 linked to disease severity and clinical outcomes. 
  
Introduction 
The evolution of liver cirrhosis to clinical liver related outcomes resulting from portal 
hypertension is not simply dictated by architectural and haemodynamic changes within the 
liver. Rather, advancing liver disease results in deleterious changes in a number of critical 
organs and the understanding of this process is a central aspect in the clinical management 
of cirrhotic patients.  
The hyperdynamic circulation in cirrhosis is characterised by increased cardiac output and 
decreased systemic vascular resistance with low arterial blood pressure [1-3]. Splanchnic 
vasodilation, with a resulting decrease in the effective central volume, has been proposed as 
an important driver of the hyperdynamic circulation [1, 4]. Associated with splanchnic 
vasodilation is an increase in portal vein blood flow which maintains and perpetuates portal 
hypertension [5]. Further, architectural and haemodynamic changes in the heart,  spleen, and  
kidney have also been shown to occur and have important pathophysiological consequences. 
For example, cirrhotic cardiomyopathy is characterised by increased cardiac output with a 
sub-optimal ventricular response to stress, and structural and electrophysiological 
abnormalities [2]. Cardiac dysfunction associated with cirrhosis has been shown to be an 
important prognostic determinant of mortality at 1 year [6]. Renal vasoconstriction, related 
to splanchnic vasolidation, portal hypertension and activation of compensatory 
neurohormonal systems, is a precursor for the development of hepatorenal syndrome [3, 6, 
7]. In cirrhosis, splenic enlargement may result from portal venous congestions and/or 
hyperplasia. In association, the splenic artery is suggested to dilate [8], and recent data 
suggests that the splenic artery to hepatic artery diameter ratio can predict the development 
of ascites and varices [9].  Splenic stiffness has been found to have a strong association with 
portal hypertension [10, 11]. However, we have an incomplete understanding of how changes 
in the different organs are inter-related and their temporal relationship.  
The importance of assessing critical organs in liver cirrhosis in a holistic fashion is 
illustrated by the current controversy surrounding beta-blockers in liver cirrhosis. The debate 
regarding the safety of beta-blockers focuses on whether the beneficial effects of beta-
blockers in liver cirrhosis, centred around a reduction in cardiac output, splanchnic 
vasodilation and portal inflow and improvement in intrahepatic resistance (alpha 1 blockade), 
is counterbalanced by deleterious effects in advanced cirrhosis centred on a reduction in renal 
perfusion and cardiac output as described previously [12]. A key limitation in being able to 
define the critical window [6, 13] of benefit of beta-blockers versus harm is the lack of robust 
non-invasive tools to measure changes across organs in a contemporaneous manner. If this 
could be done, treatment could be indiviudalised more effectively. This does not currently 
occur in clinical practice, in a consistent manner, as the tools for measurement are blunt (e.g. 
heart rate) or invasive ( hepatic venous pressure gradient measurement (HVPG)). 
Recent advances in non-invasive magnetic resonance imaging (MRI) techniques allow the 
assessment of blood flow to organs [14], tissue perfusion [15, 16], and compositional changes 
including fibrosis and inflammation,  [17-19], in the key organs associated with cirrhosis. Until 
now, such measures have only been examined in single organs rather than using a 
comprehensive multi-organ approach in a single scan session.   
Our aim was to assess the feasibility of performing MRI in contemporaneous organs of the 
liver, heart, spleen and kidneys in patients with compensated cirrhosis. We aim to describe 
the differences in quantitative MRI measures within these organs between healthy 
volunteers, and patients with compensated cirrhosis and decompensated cirrhosis. As proof 
of concept, we explore whether differences in MRI parameters are observed in patients with 
future clinical liver related outcomes.  
 
Materials and Methods 
Study Population 
Sixty patients were consecutively recruited from a compensated cirrhosis (CC) cohort study, 
a prospective study initiated in 2010 focussed on tracking liver disease progression. Here, 
baseline measures collected for this cohort are reported. Institutional and local research 
approval was gained (10/H0403/10). Patients were recruited with evidence of cirrhosis 
(confirmed by a combination of biopsy, clinical and radiological criteria) and no evidence of 
decompensation (ascites, significant jaundice, hepatic encephalopathy and variceal bleeding), 
hepatocellular carcinoma and portal vein thrombosis. Exclusion criteria included orthotopic 
liver transplantion, ischaemic heart disease, alcoholic cardiomyopathy (defined by clinical 
evidence of systolic dysfunction) and valvular heart disease.  
For comparator measures, we prospectively recruited two additional groups – healthy 
volunteers and decompensated cirrhotics. Fourty healthy volunteers were recruited who had 
no major co-morbidty including cardiovascular or chronic liver disease. Seven ambulatory, 
decompensated cirrhosis patients were recruited, defined as Baveno 3 or 4 stage (ascites, 
encephalopathy or previous variceal bleed); exclusion criteria included portal vein 
thrombosis, the presence of hepatocellular carcinoma (HCC), and orthotopic liver 
transplantation . Subjects attended on a single study day following an overnight fast. 
Statistical power to assess the difference between groups was determined for each MRI 
parameter at a power of 80 % and significance level of 5 %. 
Patients were invited back for research visits on a six monthly basis to assess for a liver related 
clinical outcome as defined by ascites (needing paracentesis or diuretic therapy), grade 3 or 
grade 4 encephalopathy, variceal haemorrhage requiring endoscopic therapy and emergency 
admission, HCC (as defined by EASL criteria) and liver related death. For patients who declined 
follow up visits, we obtained their consent to access relevant medical records (both family 
practitioner and hospital records) to record clinical outcomes.  
 
Multiorgan MRI Protocol 
All participants were scanned following a 6-hour fast, with MRI scans carried out between 
8am-12pm. Imaging was performed on a 1.5 T Philips Achieva MRI scanner (Best, 
Netherlands) using a 16-element Torso receive coil and body transmit coil. MR measures were 
collected on four organs: liver – blood flow in the portal vein (PV) and hepatic artery, liver 
perfusion and tissue T1; spleen and superior mesenteric artery (SMA) - blood flow assessed in 
the splenic and SMA, splenic tissue perfusion and tissue T1; renal – blood flow in right renal 
artery, kidney volume, renal tissue perfusion and tissue T1; heart - aortic blood flow corrected 
for body surface area (BSA) to yield cardiac index and left ventricular (LV) wall mass as a 
measure of cardiac strain. This non-invasive protocol took less than one hour for hepatic (~ 
20 minutes), spleen, SMA and renal (~ 15 minutes), and cardiac (~ 10 minutes) measures. The 
following describes the acquisition protocol parameters. 
Organ volume: First multi-slice balanced turbo field echo (bTFE) localiser images were 
acquired in three perpendicular orientations to locate organs and vessels of interest for slice 
positioning, and from which to estimate organ (liver, kidney and spleen) volume.  
Blood Flow measures: Phase contrast (PC)-MRI was used to quantify vessel lumen cross-
sectional area (CSA), velocity and bulk blood flow in vessels within each system. A TFE 
technique (2 averages, TFE factor 4–6 dependent on subjects’ heart rate) was used with a 
single slice perpendicular to the vessel of interest. 15 phases were collected across the cardiac 
cycle using specified velocity encoding for each vessel (portal vein 50cm/s, 
hepatic/splenic/renal arteries 100cm/s, superior mesenteric artery 140cm/s). Each vessel 
measurement was acquired during a 15-20s breath hold.  
Perfusion of the liver, spleen and kidney: Respiratory-triggered flow alternating inversion 
recovery arterial spin labelling (FAIR-ASL) [15, 16](post-labelling delay 1100ms, balanced fast 
field echo (bFFE) readout) was used to measure tissue perfusion in the liver, spleen and renal 
tissue. Liver perfusion data was acquired in 3 sagittal slices through the right lobe (slice gap 5 
mm, 60 ASL pairs in ~ 8 minutes), spleen/renal perfusion data was collected in 5 contiguous 
coronal-oblique slices through the spleen and long axis of the kidney (30 ASL pairs in ~ 
5minutes). An equilibrium base magnetisation M0 and T1 image was acquired for each slice 
orientation for perfusion quantification. 
Relaxometry of the liver, spleen and kidney: A modified respiratory-triggered inversion-
recovery sequence [16, 19, 20] was used to measure tissue T1 in the liver, spleen and kidney, 
with slices geometrically matched to the ASL data. For liver tissue, a  fat suppressed spin-echo 
echo planar imaging (SE-EPI) readout was used to ensure no influence of fat on T1 measures. 
Data was collected at 13 inversion times (TI) (100-1200 ms in 100 ms steps, and 1500 ms) with 
minimal temporal slice spacing between the three slices (65 ms) collected in a descend slice 
order, in an acquisition time of ~ 2 minutes. For the spleen and kidney, a bFFE readout was 
used and data acquired at 9 TIs (100-900 ms in 100 ms steps) with minimal temporal slice 
spacing (144 ms), both ascend and descend slice order acquisitions were acquired to increase 
the dynamic range of inversion times [16, 19, 20]  in ~ 3 minutes. Subjects were confirmed to 
not have excess iron [16, 19, 20]. 
Cardiac assessment: Cardiac output was measured using a PC-MRI of the aorta with 30 phases 
and velocity encoding of 200 cm/s in ~ 1 minute whilst free breathing. Short-axis cine images 
were acquired to measure LV wall mass using a multi-slice TFE sequence (12 slices, 30 phases, 
3 slices acquired per 15-20 s breath hold).  
Data Analysis 
Blood Flow Measures: ‘Q-flow’ software (Philips Medical Systems) was used to analyse PC-
MRI data. For each vessel, a region-of-interest (ROI) was drawn to estimate flow by averaging 
the flow velocity values within the ROI and multiplying by vessel lumen CSA. Mean flow was 
calculated by averaging the flow rates for each cardiac phase across the cardiac cycle. 
Perfusion: Supplementary Figure 1 shows the analysis procedure for ASL data performed 
using MATLAB and/or IDL routines. Each ASL label/control image was motion corrected to the 
base magnetisation M0 image using in-house software. Individual perfusion weighted images 
(control-label) were calculated, inspected for motion (exclude>1 voxel movement) and 
averaged to create a single perfusion-weighted image (ΔM). ΔM, M0 and T1 maps were used 
in a kinetic model [21] to compute tissue perfusion maps. A binary mask of each organ (see 
Relaxometry section) was formed and used to calculate the mean liver, spleen and renal 
cortex perfusion.  
Relaxometry: Inversion recovery data were fit to a 2-parameter model to generate T1 and M0 
maps. Binary organ masks were formed from the M0 image, and major blood vessels further 
segmented by excluding voxels with a T1 > 1500 ms. Median T1 values were calculated within 
liver and spleen masks. For the kidney mask, a histogram of T1 values was formed to yield two 
peaks originating from the renal cortex and medulla (Supplementary Fig. 1a), and the median 
T1 values of the renal cortex and medulla calculated. 
Volume: Analyze® (Mayo Clinic) was used to draw an ROI around each organ (liver, kidney, 
spleen) within each slice, and total organ volume calculated by summing across slices.  
Cardiac: Cardiac MRI data was analyzed using ViewForum software (Philips Medical Systems, 
Best, Netherlands). PC-MRI data of the aorta was analyzed by computing the stroke volume 
and heart rate, and multiplying these parameters to yield cardiac output. This software was 
also used to draw wall contours from which LV wall mass was calculated. Both cardiac output 
and LV wall mass are presented corrected for BSA [22]. 
 
Validation of MR measures 
T1 Relaxometry of the Liver:  We assessed liver histology in a cohort of cirrhosis patients who 
previously had T1 mapping of the liver on a 1.5 T scan  [19, 20], all MRI scans were collected 
within 3 months of liver biopsy. Liver biopsies were obtained via eith er the percutaneous or 
the transjugular route from patients with METAVIR fibrosis stage 4. Patients were fasted 
overnight before the procedure and biopsies were carried out by experienced operators. 
Biopsies were stained with hematoxylin and eosin, picrosirius red (PSR) and Perls’ Prussian 
blue stains. All biopsy data were analysed by a single experienced pathologist blinded to MRI 
data. The percentage of fibrous tissue relative to the total biopsy area was estimated for each 
biopsy by visual morphometry [17]. A Spearman’s rank correlation coefficient (in terms of R 
value) was computed between the continuous variables of visual morphometry and liver 
tissue T1.  
All CC patients had a blood sample to assess non-invasive markers of liver fibrosis (ELF 
(enhanced liver fibrosis) score). In addition, in all CC patients transient elastography 
evaluation was performed using FibroScan® (EchoSens, Paris, France) to provide a liver 
stiffness measure (LSM) in kPa. The Fibroscan® measure was repeated to obtain 10 readings 
and a median LSM value calculated. Spearman’s rank correlation coefficients (R value) are 
presented between ELF and LSM with a statistical significance threshold of p <0.05. 
ASL Perfusion of the Liver: In all patients, measures of Indocyanine green (ICG) were 
performed and plasma disappearance rate (ICG-PDR, percentage of ICG eliminated in 1 
minute after an ICG bolus) (%/min), and its retention rate at 15 minutes (ICGR15, the 
circulatory retention of ICG during the first 15 minutes after a bolus injection (%)) computed. 
A Spearman’s rank correlation coefficient was performed beyween ICG-PDR and ICGR15 and 
liver perfusion as measured using arterial spin labelling. Correlation coefficients are presented 
in terms of R value with a statistical significance threshold of p <0.05. 
Repeatability of Multiparametric MRI Measures: To determine the between session 
repeatability of MRI measures, the intra-subject Coefficient of Variation (CoV) (defined as the 
standard deviation/mean) of multiparametric MRI measures were assessed. A subset of 10 
healthy participants (age 23-37 years, body mass index 20-26 kg/m2) had three scans, at least 
one week apart and within four weeks, at the same time of day and after an overnight fast to 
limit diurnal and dietary variability.  Supplementary Table 1 provides the CoV measures. 
 
Statistical Analysis 
 
All statistical analysis was performed using Prism 6 (GraphPad Software, Inc., La Jolla, CA). A 
Shapiro-Wilk normality test was applied to data collected on each MRI parameter. Normal 
data is expressed as mean (SEM) and non-normal as median (interquartile range, IQR) across 
each group. Tests between the three patient groups were made using a one-way analysis of 
variance (One-Way ANOVA) with Bonferroni correction for normally distributed data, else a 
Kruskal-Wallis test was performed to assess probable differences between the groups, with 
post-hoc Tukey’s test where significant differences were identified.  
To compare results between CC patients without and those with a negative liver related 
clinical outcome, a two-tailed unpaired t-test was performed to assess differences in normally 
distributed parameters, else a Mann-Whitney U test was performed, significance was 
considered at p < 0.05. In addition, to test the probability of organ involvement in outcome, 
a survival analysis was performed providing Kaplan–Meier curves and significance of 
difference determined by log-rank test, using the 1st tertile of MRI parameters as cut-off 
values. 
Results   
The CC cohort (n=60) comprised 25 females (F)/35 males (M) of 60 ± 9 years with a range of 
aetiologies, the largest being Alcoholic Liver Disease (ALD, 21 patients, 35%), Non-Alcoholic 
Fatty Liver Disease (NAFLD, 16 patients, 27%), and Hepatitis-C Virus (HCV, 12 patients, 20%), 
with the remaining 18% of patients having primary biliary cirrhosis, hepatitis B virus, primary 
sclerosing cholangitis, autoimmune hepatitis and haemochromatosis. Mean MELD, Fib4 and 
Apri scores were 7.7±2.1, 3.4±2.3, and 1.2±1.2. Of this group, 6 patients were on beta-
blockers. The healthy volunteer (HV) group (n=40)  comprised 17F/23M subjects of 59±10 
years. The decompensated cirrhosis (n=7) (DC) group comprised 5F/2M patients of 48±13 
years, with 5 ALD, 1 NAFLD and 1 HCV and decompensation type being 4 ascites, 2 varices and 
1 encephalopathy. Mean MELD, Fib4 and Apri scores were 9.9±3.3, 3.5±1.6,  and 1.4±1.1. 
Validation of MR measures 
T1 Relaxometry of the Liver: T1 relaxation time correlated significantly with visual 
morphometry of percentage fibrosis in advanced F4 fibrosis (R=0.62, p<0.001), 
Supplementary Figure 2. As a secondary outcome, we show a significant positive correlation 
of liver tissue T1 with ELF score, R=0.65 and p< 0.001, Supplementary Figure 3. In addition, a 
highly significant correlation of liver tissue T1 with the LSM from Fibroscan® was 
demonstrated (R=0.68, p< 0.001), Supplementary Figure 3.  
ASL Perfusion of the Liver: In all patients ICG measures were collected and correlated with 
liver perfusion as measured by ASL. A weak but significant positive correlation was 
demonstrated between liver perfusion measured using ASL and ICG-PDR (R=0.46, p=0.0016), 
and negative correlation with ICGR15 (R=0.46, p=0.0011), Supplementary Figure 4.  
Repeatability of Multiparametric MRI Measures: Intra-subject repeatability for all the 
multiparametric MRI measures is provided in Supplementary Table 1. Measurement of MR 
parameters is highly repeatable with a CoV of <10 % in assessment of volume, T1 relaxometry 
measures, and ASL perfusion.   
 
Changes in Compensated and Decompensated Cirrhosis compared to Healthy Volunteers 
In the following section, MRI measures are provided for each organ studied – liver, spleen and 
SMA, renal and cardiac - and compared across stage of disease severity i.e. HV vs CC vs DC.   
Liver: Figure 1 shows the changes measured in the liver across the three groups. Liver volume 
was significantly greater in CC patients compared to both HVs and DC patients (p=0.006). We 
observed liver tissue T1 progressively increased with disease severity, from HV to CC and DC 
(p<0.001), with statistically significant differences between HV and CC (p<0.001), and the CC 
and DC groups (p=0.01). Portal vein CSA significantly increased in CC compared to HVs 
(p<0.001). The cross sectional area of the hepatic artery (HA) increased with disease severity 
(though not significant p=0.09). Total hepatic blood flow (PV+HA flow) significantly increased 
with disease severity (p = 0.03). The percentage contribution of PV flow to total hepatic flow 
(PV flow + HA flow) did not significantly change with liver disease severity (77.9±1.2%, 
72.8±1.9%, and 74.5±6.7% for HV, CC, and DC respectively). Liver perfusion significantly 
reduced with disease severity (p<0.001), with statistically significant differences between HV 
and CC (p<0.001), and the CC and DC groups (p<0.01).   
Spleen and superior mesenteric artery:  Figure 2 shows changes in the spleen and SMA across 
the groups. Spleen volume increased in CC and DC compared to HVs (p<0.03; 206±16ml,  
459±34ml, and 490±112ml for HV, CC, and DC respectively), with spleen T1 increasing with 
disease severity. No significant difference was found in CSA of the splenic artery, whilst splenic 
artery bulk flow significantly increased with disease severity (p<0.001). Superior mesenteric 
artery bulk flow showed an increasing with disease severity. Spleen tissue perfusion 
significantly decreased with disease severity (p<0.001, 151±7ml/100g/min, 
120±6ml/100g/min, and 82±9ml/100g/min for HV, CC, and DC respectively).  
Renal:  Figure 3 shows changes across the groups.  No significant difference is seen in total 
renal volume between the HV, CC and DC groups. A significant reduction in renal cortex T1 (p< 
0.001) was demonstrated with disease severity, a trend for reduced T1 was found in the renal 
medulla but this was not significant. No significant difference was found in CSA of the renal 
artery or renal artery bulk flow, but flow per beatreduced with disease severity. No significant 
difference in renal cortex perfusion was found between the HV, CC, and DC groups. 
Cardiac: Figure 4 shows cardiac parameters across the groups. Cardiac index significantly 
increased with disease severity (p=0.005). This was driven by the increase in heart rate with 
disease severity (p<0.001, 59.6±1.6, 67.2±1.6, 76.2±3.1 beats per minute (bpm) for HV, CC, 
and DC respectively), no significant change in stroke volume was found with disease severity. 
BSA corrected cardiac LV wall mass was significantly differet across the groups (p=0.02; 
39.0±1.1, 34.0±1.7, 22.3±2.4 g/m2 for HV, CC, and DC respectively). 
 
Assessment of baseline MR parameters related to a future clinical outcome in patients with 
compensated cirrhosis at baseline  
Here, we present baseline MRI data for those compensated cirrhosis patients who developed 
a liver related outcome. Of the 60 patients with compensated cirrhosis at baseline (mean 
MELD score 7.7), 11 patients (18%) developed a future liver related outcome. The median 
number of days from MRI scan to a liver related outcome was 1001 (range: 59-2304). 7 had 
ascites, 1 developed encephalopathy, 1 developed a variceal bleed, 2 had hepatocellular 
carcinoma (HCC). Of these 11 patients, 7 patients died of a liver related cause after the first 
liver related outcome; liver failure (4 cases) and HCC (3 cases) as listed on the death 
certificate.  
The patients with an outcome were of 59±6 years, 6M/5F, and aetiology comprising 4 HCV, 5 
ALD, 1 NAFLD, and 1 HBV. Figure 5 shows how those MR parameters found to have a 
significant difference between HV, CC and DC patients relate to clinical liver related outcomes. 
There was no significant difference in liver volume between CC patients with and without a 
LRO. In contrast, liver tissue T1 was significantly higher (p=0.01) in those CC patients with a 
clinical outcome (834±36ms) compared to those without (719±10ms). The CSA of the portal 
vein was not significantly different between CC patients with and without a clinical outcome. 
Total hepatic blood flow was significantly (p=0.05) lower in those with outcomes 
(13.4±7.6ml/s) compared to those patients with no outcomes (17.8±6.0ml/s). Perfusion 
measured in the right lobe of the liver was significantly lower (p<0.01) in those patients with 
an outcome (clinical LRO: 95.8±9.5ml/100g/min, no LRO: 160±8.0ml/100g/min). No 
significant difference was found in spleen volume or splenic T1 between those CC patients 
with and without outcomes, but splenic perfusion was lower and SMA blood flow higher. 
Renal cortex T1 was significantly shorter in those CC patients with an outcome (919±28ms) 
compared to those with no outcome (1012±11ms). There was no significant difference in 
cardiac measures of cardiac index or LV wall mass index between those CC patients with and 
without a clinical outcome. Figure 6 shows the use of tertile cut-off points (as used in [23]) of 
liver perfusion, liver T1 and renal T1 used to compute Kaplan-Meier survival curves. These MRI 
parameters were significant predictors of liver related outcomes. 
Discussion  
We have shown that it is feasible to study changes in cirrhosis representing the flow, 
volume, composition and perfusion in critical organs (liver, kidney, spleen and heart) in a 
contemporaneous fashion in a single scan session using quantitative MRI without the 
requirement of injection of a contrast agent. Individual MR components change with disease 
severity, as illustrated by Figure 7, and taken together this data provides a comprehensive 
evalution of cirrhosis relating to aspects of structure and haemodynamics. Furthermore, a 
subset of MRI markers measured at baseline (i.e. liver T1, liver perfusion and renal cortex T1) 
differentiate two groups of CC patients, those who develop or do not develop a future liver 
related clinical outcome up to 7 years later (Figures 5 and 6). 
  The study highlights two conceptual aspects that are coherent with our current 
understanding of how liver disease progresses. Firstly, structural changes as evidenced by  
changes  in organ volume ( i.e. spleen and liver) and compositional change ( i.e. increased liver 
T1 and splenic T1) relate to increasing disease progression from the spectrum of healthy 
volunteers to decompensated cirrhosis. Secondly, how changes in haemodynamics both to 
and within the organ evolve with progressive disease. This is exemplified by the reduction in 
both liver and splenic perfusion. Despite the small size of the DC group, it is interesting to 
note that the reduction of hepatic perfusion occurs in the context of increased total hepatic 
blood delivery in the CC and DC group, though this only results in an increase in normalised 
hepatic blood flow between the HV and DC group (Supplementary Figure 5).  The reduction 
in liver volume that occurs in decompensated cirrhosis compared to compensated cirrhosis, 
as previously shown in [24], suggests that this is not related to a larger mass of liver tissue to 
supply. We hypothesise two explanantions for this discordance. Firstly, intra-hepatic shunting 
may occur, although using our current MR methods we do not have the spatial resolution to 
directly visualise shunts. Secondly,  in liver disease it is difficult to use normalised hepatic 
blood flow as a measure of global perfusion due to the underlying changes in liver 
composition. The deposition of fat, interstitial oedema and inflammatory cells can all 
potentially  increase liver volume. As the liver starts decompensating, these features subside 
and in addition there is a loss of hepatocyte volume relative to an increasing amount 
extracellular matrix [25]. This highlights the importance of measuring perfusion rather than 
blood flow per se. 
The increase in splenic artery blood flow is largely compensated for by the increase in 
spleen volume, with a trend for reduction in normalised splenic flow (Supplementary Figure 
5) in agreement with the significant reduction in perfusion. The increase in splenic T1 also 
suggests that angio-architectural changes occur within the splee, perhaps related to fibrosis. 
Finally, there was a trend for reduced renal perfusion, in the context of maintained renal 
artery bulk flow and increased kidney volume, in agreement with a reduced normalised renal 
blood flow, Supplementary Figure 5.  
Of the 60 compensated cirrhosis patients, six were on beta-blockers with this sub-
group showing a significant reduction in splenic artery cross-sectional area, mean velocity and 
flux, spleen perfusion and portal vein mean velocity, thus increasing the CC cohort group 
variance in these measures. In addition, the DC sample size is currently underpowered to 
determine significant incremental changes, except in T1 relaxometry measures; this remains 
work in progress. 
The significant difference in baseline MRI parameters in those patients at risk of 
clinical events, within an average follow up period of 3 years and maximium follow up of 7 
years, is very encouraging. In this study 18% (11) patients had a negative clinical outcome, 
this is a similar sample size to a recent study of events using multiparametric MRI of the liver 
alone and an associated Liver Inflammation and Fibrosis (LIF) score in which 10 patients (11%) 
were studied [26]. In the current study, we had a higher LRO compared with previous studies 
(4% in a transient elastography study [27] and 13% in a ELF study [28]). The increased liver T1 
(a marker of structural severity) and reduced liver perfusion (a marker of haemodynamic 
severity) in patients with early compensated liver cirrhosis achieving future liver related 
clinical outcomes has biological plausibility and provides a link between surrogate bio-imaging 
signals and robust clinical end points.  The relevance of the strong relationship of renal cortex 
T1 to both disease severity and clinical outcomes is novel. Two studies, in patients with 
cirrhosis,  have suggested changes in T1 occur within the cortex of the kidney, but until now 
these studies have been based on signal intensity changes of T1-weighted images [29, 30], 
with no quantitative measures of T1 relaxation times having previously being reported. These 
previous studies suggest that the mechanism and physiology of reduced renal T1 is decreased 
water content in the renal cortex due to renal hypoperfusion. Whilst the overall blood flow 
to the kidneys was maintained in our study, there was both a trend toward reduced renal 
perfusion, reduced renal artery flow per beat decreased and kidney volume increased (Figure 
3), with a significant reduction in normalised bulk renal blood between healthy volunteers 
and CC patients (Supplementary Figure 5). Thus it is intriguing to speculate that regional 
vasoconstriction, driven by neurohormonal mechanisms, accounted for differential water 
content and reduced T1. If this is proven to be the case, this has direct implications for the 
treatment of hepatorenal syndrome.  
The overall picture that emerges from this study is consistent with our current 
understanding of the hyperdynamic circulation and the peripheral arterial vasodilatation 
hypothesis [4] . With advancing liver disease, reflected by structural changes within the liver 
(prolonged liver T1 values, Figure 1) and haemodynamic changes in the liver (reduced liver 
perfusion, Figure 1), there is a predicted rise in portal pressure (calculated from MRI data as 
a surrogate measure of HVPG [20] shown in Supplementary Figure 6). Pooling of blood in the 
splanchnic circulation as evidenced by increased SMA bulk flow and splenic artery bulk flow 
(Figure 2) perpetuates this raised portal pressure. To accommodate the reduced effective 
central volume, the cardiac index increases in association with a raised heart rate (Figure 4). 
Importatly this compensatory mechanism may be fragile as highlighted by the reduced LV 
wall mass in decompensated cirrhosis in our study and by others [31]. The decompensated 
cirrhosis group, albeit small in number, were ambulatory in our study. It is plausible that acute 
insults, including sepsis, that lead to hospitalisation tip the balance of these compensatory 
mechanisms.  Recently, it has been proposed that vasodilation occurs in a differential manner 
in regional beds. Using PC-MRI angiography, McAvoy and colleagues [32] found a reduction 
in total renal blood flow in patients with advanced liver disease compared to healthy 
volunteers but an increase in total hepatic blood flow and superior mesenteric artery flow. 
Our data supports this concept of differential visceral blood flow in cirrhosis .  
Here we present validation of our MRI measures against the gold standard, showing 
the correlation of T1 with the continuous biopsy variable of visual morphometry in METAVIR 
fibrosis stage F4, in agreement with previous reports in literature across a wider range of 
fibrosis scores obtained from histology [17, 19]. Further, we show that liver perfusion 
assessed in this CC cohort shows a significant correlation with Indocyanine green (ICG-PDR 
and ICGR15). A recent study [33] assessed ICG continuous clearance and HVPG measurement 
against 2D PC-MRI of portal venous and hepatic arterial flow. They were able to demonstrate 
useful correlates that suggest benefits further development of MRI protocols for liver blood 
flow. We acknowledge ICG-PDR and ICGR15 are surrogate and not true measures of 
perfusion. Formal ICG clearance would be the optimal method, but this requires invasive 
transjugular hepatic venous sampling and simultaneous peripheral arterial sampling in 
patients receiving a continuous peripheral ICG infusion, as such this invasive procedure is far 
less practical. Doppler ultrasound has been widely used to assess blood flow in liver disease 
[34, 35], and has the advantage of wide availability. However, disadvantages include intra- 
and inter-observer variation, with reported intra-class variation of 0.49 [36] due to 
inadequate standardisation of protocols including anatomical site, doppler beam angle and 
operator experience. Annet et al. showed PC-MRI parameters have the sensitivity to detect a 
significant difference between HV and cirrhotics not reflected in doppler ultrasound [34]. 
Doppler ultrasound has been shown to underestimate blood flow and be less reproducible in 
comparsion to PC-MRI [37], here we have shown the CoV of PC-MRI to be less than 5% in 
healthy volunteers [38], further MRI has been shown to be more reliable with respect to inter-
observer variability than Duplex Doppler Ultrasound [39]. Several studies have used 
computed tomography to assess portal vein and hepatic artery blood flow, but this is limited 
by ionising radiation exposure [40]. 
This study has a number of clinical implications. Firstly, understanding the benefit 
versus risk of existing and emerging therapeutics. Betablockers are used as standard care in 
the setting of portal hypertension. However, non-selective betablockers may be potentially 
deleterious after a critical threshold or window period has traversed. It remains unclear when 
that period exactly occurs, but this is likely to be related to diminishing cardiac output and a 
reduction in renal blood flow [6]. The concept of using MR protocols to assess response to 
betablockers has been explored by the Edinburugh group. They used PC-MRI to show a 
significant reduction in cardiac output (as measured by superior aorta blood flow) but 
maintenance of blood flow in other vessels (SMA, portal vein, hepatic artery, azygous vein) 4 
weeks after commencing beta-blocker therapy, though this was in a small cohort of patients 
who were heart rate responders (n = 9) [13].  Furthermore, using MRI protocols to assess 
novel drug compounds has been highlighted by the recent report of serelaxin providing 
therapeutic potential in renal dysfunction in cirrhosis. In this study selective renal vasodilation 
did not appear to be offset by a reduction in systemic blood pressure or hepatic perfusion 
[41]. Taken together with our findings, the vision should be to use MRI protocols to assess 
response at an individual level and thus provide tailored therapy which is effective and safe. 
A further application is whether this MRI protocol could serve as a prognostic tool for overall 
liver outcomes or specific complications. There is a growing body of literature showing the 
promise of non-invasive markers of liver fibrosis for prognostic performance [42, 43]. The 
ability of two simple scores Fib4 and APRI to differentiate  outcomes in early compensated 
cirrhosis, as reproduced in this study (Figure 5) cautions against positioning MRI as a generic 
prognostic tool. However, the difference in parameters between patients with/without 
significant clinical outcomes is suggestive of the potential to use these parameters for 
prediction and would be an understandable ambition in the era of emerging anti-fibrotic 
compounds. Larger studies are required to detemine clinical utility of these promising 
multiparametric measures related to LROs [44]. 
This study was designed as a proof of concept study to assess the feasibility of using 
MRI to assess different organs in cirrhosis and confirms this is possible. Importantly, the scan 
time for the present protocol is one hour. Whist we have obviated the requirement of 
intravenous contrast, the scan time can now be reduced by omitting parameters which have 
been found to be non-contributory. This will be important for patient compliance and 
reducing cost and burden on radiology service provison time for future implementation into 
clinical practice. Whilst the MR picture obtained provides an overview it is by no means an 
exclusive assessment of the hyperdynamic circulation. For example, the current protocol does 
not provide an assessment of systemic vascular resistance nor does it delineate intrahepatic 
shunts which we have postulated to underpin the marked reduction in liver perfusion. We 
deliberately chose aspects of MRI measurements that have been validated previously by our 
group and others based on comparison to gold standard reference tests including invasive 
angiography and liver biopsy. The current imaging protocol has been performed on 1.5 T but 
can easily be applied at 3T, which provides higher signal-to-noise ratio and spatial resolution. 
Demonstrating that monitoring of therapy with MRI protocols can change hard clinical 
outcomes and is cost effective within a multicentred randomised controlled trial will be 
required before considering implementation into clinical care. 
We have shown that quantitative MRI can provide a global picture of cirrhosis by 
measuring aspects of flow, volume, composition and perfusion in critical organs. The change 
of key parameters including liver T1, liver perfusion and renal cortical T1 in both progressive 
disease and the differences detected in liver related clinical outcomes has tangible utility in 
the  understanding and treatment of the complications of chronic liver disease.  
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Figure Legends 
 
Fig. 1. Change in the liver in healthy volunteers (HV), compensated cirrhosis patients (CC) 
and decompensated patients (DC). A) liver volume. B) T1 within liver tissue. C) Portal vein 
cross sectional area . D) Portal vein bulk flow. E) Hepatic artery cross sectional area. F) Hepatic 
artery bulk flow. G) Total hepatic blood flow (portal vein bulk flow + hepatic artery bulk flow). 
H) Perfusion of liver tissue. Data analyzed using one-way ANOVA, followed by the Tukey post 
hoc test. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001. 
 
Fig. 2. Changes in the spleen and Superior Mesenteric Artery in healthy volunteers (HV), 
compensated cirrhosis patients (CC) and decompensated patients (DC). A) Spleen volume. 
B) Spleen T1. C)  Splenic artery cross sectional area. D) Splenic artery bulk flow. E) Superior 
mesenteric artery cross sectional area. F) Superior mesenteric artery bulk flow G) Splenic 
tissue perfusion. Data analyzed using one-way ANOVA, followed by the Tukey post hoc test. 
*p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001. 
 
Fig. 3. Changes in the kidney in healthy volunteers (HV), compensated cirrhosis patients (CC) 
and decompensated patients (DC). A) Total renal volume. B) Renal cortex and medulla T1. C) 
Renal artery cross sectional area. D) Renal artery bulk flow. E) Renal artery flow per beat. F) 
Renal cortex perfusion. Data analyzed using one-way ANOVA, followed by the Tukey post hoc 
test. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001. 
 
Fig. 4. Changes in the cardiac function between healthy volunteers (HV), compensated 
cirrhosis patients (CC) and decompensated patients (DC). A) Cardiac Index. B) Body surface 
area corrected left ventricular wall mass C) Heart rate. Data analyzed using one-way ANOVA, 
followed by the Tukey post hoc test. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001. 
 
Fig. 5. Baseline MRI parameters in CC patients with and without liver related outcomes. 
Liver: A) Hepatic volume. B) Portal vein blood flow. C) Total hepatic blood flow. D) Liver 
perfusion. E) Liver T1; Spleen and SMA: A) Splenic volume. B) Splenic artery bulk flow. C) SMA 
bulk flow. D) Splenic perfusion. E) Spleen T1; Renal/Cardiac: A) Renal cortex T1. B) Cardiac 
Index. C) Left ventricular wall mass index; Clinical measures: A) MELD. B) Apri. C) Fib4.  
 
Fig. 6 Kaplan–Meier curves for liver related outcome survival in compensated cirrhosis with 
patients stratified according to A) Liver T1 B) Liver perfusion and C) Renal cortex T1. A) There 
were significant differences between those with Liver T1 for the 1st tertile T1 of  793 ms (p < 
0.001). B) There was significance between liver perfusion using the 1st tertile of 125 
ml/100g/min (p < 0.001). C) There was a significant difference between renal T1 using a 1st 
tertile of 958 ms (p < 0.001). 
 
Fig. 7. Multiorgan changes demonstrated in this study in compensated and decompensated  
liver disease. 
Infographic to pictorially illustrate the changes in key organs (heart, liver, splanchnic and 
kidney) demonstrated in this study of contemporaneous MR measures in compensated and 
decompensated cirrhosis.  A hyperdynamic circulation results in increased blood flow in the 
liver, splanchnic circulation and increased cardiac output in CC patients, with further increases 
in spleen blood flow and cardiac index in DC patients. Here liver and splenic perfusion was 
shown to be reduced in CC patients compared to the HV group, and perfusion in these organs 
is further reduced in DC patients. No significant change in renal perfusion was found between 
CC and DC patients and the HV group. Tissue demonstrated an increase in T1 in the liver in CC 
patients which further increased in DC patients, spleen T1 was only significantly different from 
the HV group in DC patients. In contrast renal T1 was reduced in CC patients and further 
reduced in DC patients compared to HVs. Left ventricular wall mass significantly reduced in 
DC patients compared to HVs, whilst liver volume was found to increase only in CC patients, 
and spleen volume was increased in both CC and DC patients compared to HVs.  
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Supplementary Figures and Tables 
 
Supplementary Fig. 1. Analysis pipeline for A) renal and spleen, and B) liver T1 and ASL data. 
Example image analysis indicating segmentation of the kidneys, definition of cortex and 
medulla masks using histogram analysis, and the application of the renal cortex mask to an 
arterial spin labelling perfusion map allowing the interrogation of renal cortex perfusion. 
Similar steps are performed to assess perfusion and T1 values in the spleen and liver. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Supplementary Fig. 2. Liver T1 relaxation time as a measure of fibrosis as assessed by gold 
standard liver biopsy. Scatter plot of the distribution of liver T1 relaxation time with 
pathologist’s estimate of fibrosis in F4 group, based on the methods described in [17]. 
Spearman rho and p-value of correlation shown. 
 
 
 
 
 
 
 
 
 
 
 Supplementary Fig. 3. Liver T1 relaxation time as a measure of ELF and LSM. Scatter plot of 
distribution of liver T1 relaxation time with ELF and LSM as measured from  Fibroscan®, with 
Spearman rho and p-value of correlation shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 Supplementary Fig. 4. Liver perfusion as a measure of ICG-PDR and ICG_R15. Scatter plot of 
distribution of liver T1 relaxation time with plasma disappearance rate (ICG-PDR) and 
retention rate at 15 minutes (ICGR15), with Spearman rho and p-value of correlation shown.   
 
 
 
 
 
 
 
 
 
 
 
 Supplementary Fig. 5. Organ volume normalised blood flow measures in healthy volunteers 
(HV), compensated cirrhosis patients (CC) and decompensated patients (DC). Plots shown 
for normalised liver blood flow, normalised splenic blood flow, and normalised renal blood 
flow.  Data analyzed using one-way ANOVA, followed by the Tukey post hoc test. *p < 0.05, 
**p < 0.01, ***p < 0.005, ****p < 0.001. 
 
 
 
 
 
 
 
 
 
 
 
 Supplementary Fig. 6. Estimated HVPG. Estimated HVPG computed using liver T1 and splenic 
artery velocity measures, based on the model proposed in [20]. 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 1: Intra-subject repeatability for the multiparametric MRI measures. 
Abbreviations: CoV coefficient of variation; CSA cross sectional area; SMA superior mesenteric 
artery; T1 longitudinal relaxation time.  
Liver CoV 
(%) 
Spleen and SMA CoV (%) Renal/Cardiac CoV (%) 
Liver volume 4.6 Spleen volume 5.2 Renal volume 4.2 
Liver T1 1.5 Spleen T1 1.8 Cortex T1 
Medulla T1 
2.0 
1.8 
Portal vein flow 18.6 Splenic artery flow 11 Renal Artery Flow 14.4 
Portal vein CSA 9.5 Splenic artery CSA 7.3 Renal Artery CSA 11.1 
Hepatic artery 
flow 
22.7 SMA flow 7.6 Global single kidney 
perfusion 
14.9 
Hepatic artery 
CSA 
13.3 SMA CSA 5.3 ASL renal cortex 
perfusion  
9.3  
ASL Perfusion  12 Spleen perfusion 6.9 Cardiac Index 8.2  
 
 
 
 
 
 
 
Supplementary Table 2: Baseline characteristics of healthy volunteers, and the 
compensated  and decompensated cirrhosis patients.  
MR measure Healthy volunteer CC Patients DC patients  
Liver volume (ml) 1480 ± 63 1778 ± 61 1523 ± 111  
Liver T1 (ms) 637 ± 5 748 ± 14 864 ± 48  
Portal vein flow (ml/s) 11.0 ± 0.6 12.9 ± 0.8 14.9 ± 3.0  
Portal vein CSA (mm2) 93.7 ± 3.4  124.4 ± 4.9 105.3 ± 13.9  
Portal vein mean 
velocity  (cm/s) 
12.0 ± 0.6 11.0 ± 0.7 13.9 ± 2.0  
Portal vein flow per 
beat (ml) 
11.0 ±  0.6 11.9 ± 0.8 11.9 ± 2.2  
Hepatic Artery flow 
(ml/s) 
3.21 ± 0.3 4.3 ± 0.3 4.6 ± 0.9  
Hepatic Artery CSA 
(mm2) 
23.3 ± 1.1 25.4 ± 1.1 28.2 ± 3.0  
Hepatic Artery mean 
velocity  (cm/s) 
13.9 ± 1.1 17.4 ± 1.1 15.7 ± 2.9  
Hepatic Artery flow per 
beat (ml) 
3.3 ± 0.3 4.0 ± 0.3 3.7 ± 0.7  
Total hepatic flow 
(ml/s) 
14.0 ± 0.8 17.0 ± 0.9 19.2 ± 2.5  
Liver perfusion     
(ml/100g/min) 
185.1 ± 9.8 141.5 ± 7.9 100.5 ± 9.5  
Splenic volume (ml) 205 ± 16 459 ± 34 489.5 ± 112  
Splenic T1 (ms) 1031 ± 11 1044 ± 11 1075 ± 50  
Splenic Artery flow 
(ml/s) 
6.3 ± 0.5 8.5 ± 0.5 11.4 ± 1.5  
Splenic Artery CSA 
(mm2) 
30.5 ± 1.6 36.4 ± 2.8 31.5 ± 3.0  
Splenic artery mean 
velocity  (cm/s) 
21.6 ± 1.4 26.0 ± 1.5 38.6 ± 7.0  
Splenic Artery flow per 
beat (ml) 
6.6 ± 0.6 7.9 ± 0.5 9.1 ± 1.2  
SMA flow (ml/s) 4.6 ± 0.3 5.5 ± 0.3 7.7 ± 1.1  
SMA CSA (mm2) 23.6 ± 1.2 25.3 ± 1.1 26.6 ± 2.2  
SMA mean velocity  
(cm/s) 
19.7 ± 0.7 21.7 ± 0.8 30 ± 4.7  
SMA flow per beat (ml) 4.5 ± 0.2 5.0 ± 0.3 6.2 ± 0.8  
Splenic perfusion 
(ml/100g/min) 
151 ± 7 120 ± 6 81 ± 9  
Renal volume (ml) 316 ± 10 336 ± 10 355 ± 28  
Renal T1 (ms) 1318 ± 16 1295 ± 17 1240 ± 60  
Renal Artery flow (ml/s) 5.6 ± 0.2 5.7 ± 0.2 5.6 ± 0.6  
Renal Artery CSA (mm2) 20.5 ± 0.7 21.3 ± 0.8 22.1 ± 2.2  
Renal artery mean 
velocity  (cm/s) 
27.6 ± 0.8 25.9 ± 1.1 26.7 ± 4.0  
Renal Artery flow per 
beat (ml) 
5.7 ± 0.2 4.9 ± 0.2 4.5 ± 0.6  
Renal cortex perfusion 
(ml/100g/min) 
223 ± 8 215 ± 11 199 ± 26  
Cardiac Index 
(L/min/m2) 
2.42 ± 0.06 2.76 ± 0.09 3.06 ± 0.38  
Cardiac Wall mass Index 
(g/m2) 
39.0 ± 1.1 40.0 ± 1.7 22.3 ± 2.4  
Heart rate 59.6 ± 1.6 67.2 ± 1.6 76.2 ± 3.1  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 3: Characteristsics of the compensated cirrhosis patients with and 
without liver related outcome (LRO). All values shown are mean (standard deviation) except 
* which indicates median and interquartile range.  
MR measure LRO  No LRO P value 
Liver volume (ml) 1948 (521) *1728 (740) 0.25 
Liver T1 (ms) 853.7 (125) 720 (73) <0.001 
Portal vein flow (ml/s) 8.7 (6.5) 13.8 (5.7) 0.01 
Hepatic Artery flow (ml/s) 3.8 (1.9) 4.1 (2.7) 0.58 
Total hepatic flow (ml/s)    
Liver perfusion 
(ml/100g/min) 
93.3 (32.2) 162.5 (46.2) <0.001 
Splenic volume (ml) 550 (331) 432 (224) 0.14 
Splenic T1 (ms) 1001 (80) 1048 (74) 0.09 
Splenic Artery flow (ml/s) 8.2 (3.3) 8.6 (3.3) 0.79 
SMA flow (ml/s) 7.4 (3.6) *4.6 (2.8) 0.04 
Splenic perfusion 
(ml/100g/min) 
92.3 (41.8) 125.1 (39.4) 0.04 
Renal volume (ml) 348 (82) 340 (67) 0.76 
Renal T1 (ms) 
Cortex 
Medulla 
Cortoicomedullary 
difference 
 
909 (89) 
1149 (119) 
239 (44) 
 
1012 (71) 
1321 (97) 
292 (80) 
 
<0.001 
<0.001 
0.003 
Renal Artery flow (ml/s) 5.74 (1.8) 5.38 (1.8) 0.56 
Renal cortex perfusion 
(ml/100g/min) 
234 (109) 211 (60) 0.437 
Cardiac Index (L/min/m2) 2.8 (0.6) *2.7(0.7) 0.77 
Cardiac Wall mass Index 
(g/m2) 
41.9 (16.2) 39.8 (11.8) 0.86 
 
 
 
